研究交流：Ustekinumab和Vedolizumab在慢性包囊炎治疗中的比较效果——一项基于人群的研究。

IF 6.7 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-10-11 DOI:10.1111/apt.70404

Saqr Alsakarneh,June Tome,Francis A Farraye,Darrell S Pardi

{"title":"研究交流：Ustekinumab和Vedolizumab在慢性包囊炎治疗中的比较效果——一项基于人群的研究。","authors":"Saqr Alsakarneh,June Tome,Francis A Farraye,Darrell S Pardi","doi":"10.1111/apt.70404","DOIUrl":null,"url":null,"abstract":"INTRODUCTION\r\nChronic pouchitis is a major therapeutic challenge in patients with ulcerative colitis following ileal pouch-anal anastomosis.\r\n\r\nMETHODS\r\nWe conducted a real-world, propensity-matched cohort study of 856 patients from a healthcare database to compare ustekinumab and vedolizumab.\r\n\r\nRESULTS\r\nUstekinumab was associated with significantly lower relapse rates (aHR = 0.69; p < 0.001), longer time to relapse, reduced hospitalisation and decreased need for steroids or antibiotics. No differences were observed in surgery rates or therapy switching.\r\n\r\nCONCLUSION\r\nOur findings suggest that ustekinumab may offer advantages over vedolizumab in the management of chronic pouchitis.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"51 1","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research Communication: Comparative Effectiveness of Ustekinumab and Vedolizumab in the Management of Chronic Pouchitis-A Population-Based Study.\",\"authors\":\"Saqr Alsakarneh,June Tome,Francis A Farraye,Darrell S Pardi\",\"doi\":\"10.1111/apt.70404\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"INTRODUCTION\\r\\nChronic pouchitis is a major therapeutic challenge in patients with ulcerative colitis following ileal pouch-anal anastomosis.\\r\\n\\r\\nMETHODS\\r\\nWe conducted a real-world, propensity-matched cohort study of 856 patients from a healthcare database to compare ustekinumab and vedolizumab.\\r\\n\\r\\nRESULTS\\r\\nUstekinumab was associated with significantly lower relapse rates (aHR = 0.69; p < 0.001), longer time to relapse, reduced hospitalisation and decreased need for steroids or antibiotics. No differences were observed in surgery rates or therapy switching.\\r\\n\\r\\nCONCLUSION\\r\\nOur findings suggest that ustekinumab may offer advantages over vedolizumab in the management of chronic pouchitis.\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"51 1\",\"pages\":\"\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-10-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.70404\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70404","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

慢性袋炎是回肠袋-肛门吻合术后溃疡性结肠炎患者的主要治疗挑战。方法：我们对来自医疗数据库的856例患者进行了一项真实世界的倾向匹配队列研究，以比较ustekinumab和vedolizumab。结果：stekinumab显著降低复发率（aHR = 0.69; p < 0.001），延长复发时间，减少住院治疗，减少类固醇或抗生素的需求。在手术率或治疗转换方面没有观察到差异。结论：我们的研究结果表明，在慢性眼袋炎的治疗中，ustekinumab可能比vedolizumab更有优势。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research Communication: Comparative Effectiveness of Ustekinumab and Vedolizumab in the Management of Chronic Pouchitis-A Population-Based Study.

INTRODUCTION Chronic pouchitis is a major therapeutic challenge in patients with ulcerative colitis following ileal pouch-anal anastomosis. METHODS We conducted a real-world, propensity-matched cohort study of 856 patients from a healthcare database to compare ustekinumab and vedolizumab. RESULTS Ustekinumab was associated with significantly lower relapse rates (aHR = 0.69; p < 0.001), longer time to relapse, reduced hospitalisation and decreased need for steroids or antibiotics. No differences were observed in surgery rates or therapy switching. CONCLUSION Our findings suggest that ustekinumab may offer advantages over vedolizumab in the management of chronic pouchitis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.